We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 39 of 51 for:    "hidradenitis suppurativa" OR "acne inversa"

The Ohio State University Dermatology Biorepository, Molecular Biology and Genetics of Hidradenitis Suppurativa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03146676
Recruitment Status : Recruiting
First Posted : May 10, 2017
Last Update Posted : June 1, 2017
Sponsor:
Information provided by (Responsible Party):
Benjamin Kaffenberger, Ohio State University

Brief Summary:
Analysis of Gene expression and microbiome profiling in hidradenitis suppurativa to identify immunological biomarkers of disease activity.

Condition or disease
Hidradenitis Suppurativa

Detailed Description:

A variety of molecular techniques can be used to investigate diseases by analyzing protein, DNA, and RNA. Flow cytometry, PCR, histology and immunohistochemistry are assays which can identify specific cell populations and provide valuable information regarding the pathologic characteristics of those populations. Flow cytometry analyzes the surface markers of cells. Histology and immunohistochemistry further characterize surface and cellular molecules and aid in the diagnosis of certain skin diseases. Gene expression profiling allows investigators to examine the genes detectable to determine the function of the cells involved, and PCR techniques are useful for the diagnosis of certain conditions and for DNA analysis.

By procuring blood, skin tissue, and swab samples from patients with and without neoplastic and inflammatory skin disorders at the time of their appointments, the hypothesize that future translational research can be conducted on such specimens using the aforementioned techniques to further understand disease mechanisms in cutaneous disorders, and to potentially discover defective function and genetic mutations within cells from patients with neoplastic and inflammatory skin disorders. By establishing a tissue bank, we aim to lay the foundation for future work that will improve our understanding of the biology and natural history of neoplastic and inflammatory cutaneous diseases.


Study Type : Observational
Estimated Enrollment : 175 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: The Ohio State University Dermatology Biorepository, SPARC
Actual Study Start Date : April 19, 2017
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders [ Time Frame: 1 year ]
    Analysis of Gene expression and microbiome profiling in hidradenitis suppurativa to identify immunological biomarkers of disease activity


Biospecimen Retention:   Samples With DNA
Skin Tissue, Peripheral blood mononuclear cells, skin swabs, and saliva.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Any person that meets the inclusion/exclusion criteria with one active hidradenitis suppurativa lesion.
Criteria

Inclusion Criteria:

  • Seen by an OSU Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol
  • Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals
  • Willingness to participate in a research study.

Exclusion Criteria:

  • Inability to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03146676


Contacts
Contact: Rachel Moore 614-366-20025 rachel.moore3@osumc.edu
Contact: Aleitha Gates 614-366-9201 aleitha.gates@osumc.edu

Locations
United States, Ohio
OSU Dermatology East Recruiting
Gahanna, Ohio, United States, 43230
Contact: Rachel Moore    614-366-2025    rachel.moore3@osumc.edu   
Contact: aleitha gates    614-366-9201    aleitha.gates@osumc.edu   
Principal Investigator: Benjamin Kaffenberger, MD         
Principal Investigator: Jessica Kaffenberger, MD         
Sponsors and Collaborators
Ohio State University
Investigators
Principal Investigator: Benjamin Kaffenberger, MD Dermatologist
Principal Investigator: Jessica Kaffenberger, MD Dermatologist

Responsible Party: Benjamin Kaffenberger, Dermatologist, Ohio State University
ClinicalTrials.gov Identifier: NCT03146676     History of Changes
Other Study ID Numbers: 2010H0331
First Posted: May 10, 2017    Key Record Dates
Last Update Posted: June 1, 2017
Last Verified: May 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hidradenitis
Hidradenitis Suppurativa
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Infection
Suppuration